Trial: 202003113

A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

Phase

III

Principal Investigator

Thaker, Premal

Disease Site

Corpus Uteri

Learn more about this study at: clinicaltrials.gov